Metabolic Biomarkers of Pancreatic Cancer

Patients with pancreatic cancer (PDAC) are usually diagnosed in advanced often incurable disease stages. Sensitive and specific markers are critical to support diagnostic and therapeutic management. Early non-invasive detection of PDAC is challenging, but discovery of a cost-effective biomarker with high specificity and sensitivity could significantly improve treatment and survival in these patients. Unfortunately, accuracy of routine clinical marker for the detection (such as CA19–9) is not high enough for prediction and detection of early-stage PDAC.